USD 1.72
(1.74%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 121.92 Million USD | 11.02% |
2022 | 109.82 Million USD | 289.81% |
2021 | 28.17 Million USD | 8.33% |
2020 | 26 Million USD | 24.41% |
2019 | 20.9 Million USD | 56.48% |
2018 | 13.35 Million USD | -10.79% |
2017 | 14.97 Million USD | -0.03% |
2016 | 14.98 Million USD | 11.13% |
2015 | 13.48 Million USD | 87.82% |
2014 | 7.17 Million USD | 48.07% |
2013 | 4.84 Million USD | 21.88% |
2012 | 3.97 Million USD | -9.01% |
2011 | 4.37 Million USD | -11.09% |
2010 | 4.91 Million USD | -42.36% |
2009 | 8.52 Million USD | -4.42% |
2008 | 8.92 Million USD | 5.83% |
2007 | 8.43 Million USD | 33.18% |
2006 | 6.32 Million USD | 30.25% |
2005 | 4.85 Million USD | 182.49% |
2004 | 1.72 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 122.71 Million USD | 0.65% |
2024 Q2 | 139.67 Million USD | 13.81% |
2023 Q3 | 117.88 Million USD | 1.73% |
2023 Q1 | 113.14 Million USD | 3.03% |
2023 Q2 | 115.88 Million USD | 2.43% |
2023 FY | 121.92 Million USD | 11.02% |
2023 Q4 | 121.92 Million USD | 3.42% |
2022 Q4 | 109.82 Million USD | 8.63% |
2022 Q2 | 28.74 Million USD | 4.71% |
2022 Q3 | 101.09 Million USD | 251.66% |
2022 FY | 109.82 Million USD | 289.81% |
2022 Q1 | 27.45 Million USD | -2.55% |
2021 Q2 | 24.88 Million USD | 253.27% |
2021 Q4 | 28.17 Million USD | 300.0% |
2021 FY | 28.17 Million USD | 8.33% |
2021 Q1 | 7.04 Million USD | -72.92% |
2021 Q3 | 7.04 Million USD | -71.69% |
2020 FY | 26 Million USD | 24.41% |
2020 Q1 | 19.13 Million USD | -8.48% |
2020 Q2 | 19.13 Million USD | 0.0% |
2020 Q3 | 26 Million USD | 35.93% |
2020 Q4 | 26 Million USD | 0.0% |
2019 Q1 | 11.25 Million USD | -15.77% |
2019 FY | 20.9 Million USD | 56.48% |
2019 Q2 | 11.25 Million USD | 0.0% |
2019 Q4 | 20.9 Million USD | 0.0% |
2019 Q3 | 20.9 Million USD | 85.78% |
2018 Q2 | 13.55 Million USD | 0.0% |
2018 Q3 | 13.35 Million USD | -1.48% |
2018 Q4 | 13.35 Million USD | 0.0% |
2018 FY | 13.35 Million USD | -10.79% |
2018 Q1 | 13.55 Million USD | -9.46% |
2017 Q4 | 14.97 Million USD | 0.0% |
2017 Q3 | 14.97 Million USD | 30.32% |
2017 Q2 | 11.49 Million USD | 0.0% |
2017 Q1 | 11.49 Million USD | -23.29% |
2017 FY | 14.97 Million USD | -0.03% |
2016 Q3 | 14.98 Million USD | 15.65% |
2016 Q1 | 12.95 Million USD | -3.91% |
2016 Q4 | 14.98 Million USD | 0.0% |
2016 FY | 14.98 Million USD | 11.13% |
2016 Q2 | 12.95 Million USD | 0.0% |
2015 Q1 | 6.98 Million USD | -2.72% |
2015 Q3 | 13.48 Million USD | 93.07% |
2015 FY | 13.48 Million USD | 87.82% |
2015 Q4 | 13.48 Million USD | 0.0% |
2015 Q2 | 6.98 Million USD | 0.0% |
2014 Q3 | 7.09 Million USD | 45.37% |
2014 Q2 | 4.88 Million USD | 3.3% |
2014 Q1 | 4.72 Million USD | -2.54% |
2014 Q4 | 7.17 Million USD | 1.17% |
2014 FY | 7.17 Million USD | 48.07% |
2013 FY | 4.84 Million USD | 21.88% |
2013 Q4 | 4.84 Million USD | 0.0% |
2013 Q3 | 4.84 Million USD | 12.66% |
2013 Q2 | 4.3 Million USD | 1.81% |
2013 Q1 | 4.22 Million USD | 6.26% |
2012 Q1 | 994.19 Thousand USD | -77.25% |
2012 FY | 3.97 Million USD | -9.01% |
2012 Q4 | 3.97 Million USD | 0.81% |
2012 Q3 | 3.94 Million USD | -9.63% |
2012 Q2 | 4.36 Million USD | 339.07% |
2011 Q4 | 4.37 Million USD | 300.0% |
2011 Q2 | 5.06 Million USD | 363.35% |
2011 FY | 4.37 Million USD | -11.09% |
2011 Q1 | 1.09 Million USD | -77.77% |
2011 Q3 | 1.09 Million USD | -78.42% |
2010 Q3 | 1.22 Million USD | -78.73% |
2010 Q1 | 1.22 Million USD | -85.59% |
2010 Q2 | 5.77 Million USD | 370.19% |
2010 FY | 4.91 Million USD | -42.36% |
2010 Q4 | 4.91 Million USD | 300.0% |
2009 Q3 | 2.13 Million USD | 0.0% |
2009 Q4 | 8.52 Million USD | 300.0% |
2009 FY | 8.52 Million USD | -4.42% |
2009 Q1 | 2.13 Million USD | -4.42% |
2009 Q2 | 2.13 Million USD | 0.0% |
2008 Q4 | 2.23 Million USD | 0.0% |
2008 Q1 | 2.23 Million USD | 5.83% |
2008 Q3 | 2.23 Million USD | 0.0% |
2008 Q2 | 2.23 Million USD | 0.0% |
2008 FY | 8.92 Million USD | 5.83% |
2007 Q4 | 2.1 Million USD | 0.0% |
2007 Q2 | 2.1 Million USD | 0.0% |
2007 Q3 | 2.1 Million USD | 0.0% |
2007 FY | 8.43 Million USD | 33.18% |
2007 Q1 | 2.1 Million USD | 33.18% |
2006 Q2 | 1.58 Million USD | 0.0% |
2006 Q3 | 1.58 Million USD | 0.0% |
2006 Q1 | 1.58 Million USD | 30.25% |
2006 FY | 6.32 Million USD | 30.25% |
2006 Q4 | 1.58 Million USD | 0.0% |
2005 FY | 4.85 Million USD | 182.49% |
2005 Q2 | 1.21 Million USD | 0.0% |
2005 Q4 | 1.21 Million USD | 0.0% |
2005 Q3 | 1.21 Million USD | 0.0% |
2005 Q1 | 1.21 Million USD | 182.49% |
2004 Q1 | 430.06 Thousand USD | 0.0% |
2004 FY | 1.72 Million USD | 0.0% |
2004 Q3 | 430.06 Thousand USD | 0.0% |
2004 Q4 | 430.06 Thousand USD | 0.0% |
2004 Q2 | 430.06 Thousand USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Aclaris Therapeutics, Inc. | 40.22 Million USD | -203.097% |
Applied DNA Sciences, Inc. | 8.77 Million USD | -1288.788% |
Aspira Women's Health Inc. | 8.62 Million USD | -1313.284% |
Biodesix, Inc. | 94.51 Million USD | -28.998% |
BioNexus Gene Lab Corp. | 1.74 Million USD | -6899.319% |
bioAffinity Technologies, Inc. | 3.36 Million USD | -3521.903% |
bioAffinity Technologies, Inc. | 3.36 Million USD | -3521.903% |
Bionano Genomics, Inc. | 118.24 Million USD | -3.11% |
CareDx, Inc | 223.28 Million USD | 45.396% |
Check-Cap Ltd. | 1.33 Million USD | -9067.218% |
Castle Biosciences, Inc. | 86.54 Million USD | -40.884% |
DarioHealth Corp. | 38.24 Million USD | -218.797% |
Exact Sciences Corporation | 3.32 Billion USD | 96.334% |
Fulgent Genetics, Inc. | 139.82 Million USD | 12.801% |
Guardant Health, Inc. | 1.62 Billion USD | 92.51% |
ICON Public Limited Company | 7.74 Billion USD | 98.427% |
IDEXX Laboratories, Inc. | 1.77 Billion USD | 93.133% |
Illumina, Inc. | 4.36 Billion USD | 97.207% |
Intelligent Bio Solutions Inc. | 5.59 Million USD | -2078.898% |
iSpecimen Inc. | 6.07 Million USD | -1905.969% |
Standard BioTools Inc. | 159.86 Million USD | 23.733% |
23andMe Holding Co. | 206.64 Million USD | 40.999% |
Medpace Holdings, Inc. | 1.09 Billion USD | 88.895% |
Myriad Genetics, Inc. | 312.9 Million USD | 61.034% |
Mainz Biomed B.V. | 12.15 Million USD | -902.681% |
ENDRA Life Sciences Inc. | 1.09 Million USD | -11033.016% |
NeoGenomics, Inc. | 739.69 Million USD | 83.517% |
Neogen Corporation | 1.44 Billion USD | 91.533% |
Inotiv, Inc. | 588.04 Million USD | 79.266% |
Natera, Inc. | 691.79 Million USD | 82.376% |
OpGen, Inc. | 13.44 Million USD | -806.912% |
OPKO Health, Inc. | 622.47 Million USD | 80.413% |
Psychemedics Corporation | 6.59 Million USD | -1747.893% |
Prenetics Global Limited | 44.01 Million USD | -177.017% |
Prenetics Global Limited | 44.01 Million USD | -177.017% |
Precipio, Inc. | 3.67 Million USD | -3220.37% |
Personalis, Inc. | 95.65 Million USD | -27.458% |
RadNet, Inc. | 2.07 Billion USD | 94.119% |
Sera Prognostics, Inc. | 25.28 Million USD | -382.237% |
Sotera Health Company | 2.68 Billion USD | 95.462% |
Neuronetics, Inc. | 81.64 Million USD | -49.342% |
Star Equity Holdings, Inc. | 21.67 Million USD | -462.51% |
Star Equity Holdings, Inc. | 21.67 Million USD | -462.51% |
Trinity Biotech plc | 83.38 Million USD | -46.22% |
T2 Biosystems, Inc. | 62.83 Million USD | -94.045% |
Twist Bioscience Corporation | 152.97 Million USD | 20.296% |
Exagen Inc. | 34.25 Million USD | -255.982% |